Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective

被引：9

作者：

Aapro, Matti ^{[1
]}

Zhang, Li ^{[2
]}

Yennu, Sriram ^{[3
]}

LeBlanc, Thomas W. ^{[4
]}

Schwartzberg, Lee ^{[5
]}

机构：

[1] Genolier Canc Ctr, Clin Genolier, Genolier, Switzerland

[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Dept Med Oncol, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Guangdong, Peoples R China

[3] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Div Canc Med, Houston, TX 77030 USA

[4] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27705 USA

[5] West Clin, Dept Hematol & Oncol, Germantown, TN 38138 USA

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 10期

关键词：

antiemetics; CINV; nausea; NEPA; netupitant; palonosetron; vomiting; HIGHLY EMETOGENIC CHEMOTHERAPY; RANDOMIZED PHASE-III; PLACEBO-CONTROLLED TRIAL; NK1 RECEPTOR ANTAGONIST; P-MEDIATED RESPONSES; HIGH-DOSE CISPLATIN; DOUBLE-BLIND; NEUROKININ-1; RECEPTOR; 5-HYDROXYTRYPTAMINE-RECEPTOR ANTAGONISTS; ORAL COMBINATION;

D O I：

10.2217/fon-2018-0872

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention.Herein, we provide an overview of CINV, then discuss oral and intravenous NEPA, the first fixed combination antiemetic, composed of netupitant/fosnetupitant and palonosetron. We describe the main pharmacologic and pharmacokinetic characteristics of NEPA, and review the clinical evidence supporting its use in the prevention of CINV.

引用

页码：1067 / 1084

页数：18

共 104 条

[1] A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy [J].

Aapro, M. ;

Rugo, H. ;

Rossi, G. ;

Rizzi, G. ;

Borroni, M. E. ;

Bondarenko, I. ;

Sarosiek, T. ;

Oprean, C. ;

Cardona-Huerta, S. ;

Lorusso, V. ;

Karthaus, M. ;

Schwartzberg, L. ;

Grunberg, S. .

ANNALS OF ONCOLOGY, 2014, 25 (07) :1328-1333

[2] The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER) [J].

Aapro, M. ;

Molassiotis, A. ;

Dicato, M. ;

Pelaez, I. ;

Rodriguez-Lescure, A. ;

Pastorelli, D. ;

Ma, L. ;

Burke, T. ;

Gu, A. ;

Gascon, P. ;

Roila, F. .

ANNALS OF ONCOLOGY, 2012, 23 (08) :1986-1992

[3]

Aapro M, 2018, ESMO 2018 C MUN GERM

[4]

Aapro M, 2014, SUPPORT CARE CANC S1, V22, pS112

[5] A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy [J].

Aapro, M. S. ;

Grunberg, S. M. ;

Manikhas, G. M. ;

Olivares, G. ;

Suarez, T. ;

Tjulandin, S. A. ;

Bertoli, L. F. ;

Yunus, F. ;

Morrica, B. ;

Lordick, F. ;

Macciocchi, A. .

ANNALS OF ONCOLOGY, 2006, 17 (09) :1441-1449

[6] Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey [J].

Aapro, Matti ;

Ruffo, Pierfrancesco ;

Panteri, Roger ;

Costa, Stefano ;

Piovesana, Vittoria .

CANCER REPORTS, 2018, 1 (04)

[7] NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron [J].

Aapro, Matti ;

Karthaus, Meinolf ;

Schwartzberg, Lee ;

Bondarenko, Igor ;

Sarosiek, Tomasz ;

Oprean, Cristina ;

Cardona-Huerta, Servando ;

Hansen, Vincent ;

Rossi, Giorgia ;

Rizzi, Giada ;

Borroni, Maria Elisa ;

Rugo, Hope .

SUPPORTIVE CARE IN CANCER, 2017, 25 (04) :1127-1135

[8] Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program [J].

Aapro, Matti ;

Hesketh, Paul J. ;

Jordan, Karin ;

Gralla, Richard J. ;

Rossi, Giorgia ;

Rizzi, Giada ;

Palmas, Marco .

ONCOLOGIST, 2016, 21 (04) :494-502

[9]

Aapro MS, 2016, SUPPORT CARE CANCER, V24, P1

[10]

[Anonymous], 2018, NCCN Clinical Practice Guidelines in Oncology

← 1 2 3 4 5 6 7 8 9 10 →